Risk of COVID-19 among patients with respiratory illnesses and comorbidities at Eastern Province of Sri Lanka: A retrospective study

Author:

Razmy Athambawa Mohamed1,Rahman Ahamed Lebbe Failur2,Lazarus Eilean Rathinasamy3,Rajab Thuvan Raheem4,Ilahi Mohamed Meerasahib Maroosathul2

Affiliation:

1. Faculty of Applied Sciences, South Eastern University of Sri Lanka, Sri Lanka

2. Ashraff Memorial Hospital, Kalmunai, Sri Lanka

3. Department of Adult Health and Critical Care, College of Nursing, Sultan Qaboos University, Muscat, Sultanate of Oman

4. Basel Hospital, Pottuvil, Sri Lanka

Abstract

Background: There is a general belief that patients with comorbidities have a higher risk of contracting coronavirus disease 2019 (COVID-19) and subsequent death. However, there are significant gaps in understanding these risks. Objective: The study aimed to assess the risk of COVID-19 among respiratory illness patients admitted to the hospital with comorbidities. Method: A retrospective cohort study was conducted in a hospital in Sri Lanka, where the records of 428 patients with respiratory illness were studied for COVID-19 infection and comorbidities from 2020 to 2022. Results: In this sample, 67.1% had been infected with COVID-19 and 51.6% had comorbidities. The age group ≥60 years had two times higher risk for comorbidities, and the most frequently occurring condition was hypertension (58.8%). Surprisingly, the infection rate of COVID-19 among patients with comorbidities was 28% lower compared to patients with no comorbidities, but the odds ratio (OR) for dying was greater once the patient with comorbidities was infected with COVID-19 (OR = 7.5). An increased risk of death was observed for COVID-19 patients with diabetes mellitus (OR = 2), hypertension (OR = 2.5), heart diseases (OR = 4.3), and renal diseases (OR = 2.4). Conclusion: It was surprising to find that the infection rate and risk of death due to COVID-19 were lower among patients with chronic lung diseases. This could be due to early death at the beginning of the COVID-19 pandemic, less hospital admissions for patients with chronic lung diseases, or resistance to COVID-19, and these are factors that require further exploration.

Publisher

Medknow

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3